Skip to main content
. 2010 Oct 11;2011:724291. doi: 10.1155/2011/724291

Table 3.

Demographic and baseline variables of patients (n = 245) by treatment groups: Ayurvedic arms code (A–E), glucosamine (GLU), and placebo (PLB).

A B C D E PLB GLU
Number 34 33 35 33 34 34 33
Age (years, mean ± SD) 57.5 ± 7.8 56.6 ± 9.4 56.8 ± 8.1 56.2 ± 9.2 56.2 ± 9.5 54 ± 7.7 54.2 ± 8.1
Weight (Kg ± SD) 63.8 ± 11.2 66 ± 13.6 64.3 ± 13.9 63.5 ±10.5 63.8 ± 10.1 65.6 ± 11.0 65.6 ± 11.8
BMI (Mean, ±SD) 28.3 ± 4.6 28.8 ± 7.5 26.9 ± 4.4 27.7 ± 4.8 27.5 ± 4.5 28.1 ± 5.3 27.6 ± 4.4
Duration of disease (years) 3.9 6.8 4.8 5.1 5.4 4.7 5.9
Active-pain VAS 6.5 (1.2) 6.2 (1.2) 6.3 (1.4) 6.2 (1.2) 6.4 (1.3) 6.4 (1.5) 6.5 (1.4)
W-PAINpPain Pain 9.0 (3.0) 8.3 (3.5) 8.0 (3.0) 8.2 (4.0) 9.2 (3.0) 9.0 (3.7) 8.0 (3.4)
W-DIFF 27 (11.7) 27 (12.2) 25.5 (8.9) 25.0 (12.9) 27.0 (12.3) 28.2 (11.7) 26.0 (10.4)

SD: standard deviation; BMI: body mass index; VAS: visual analogue scale; W: WOMAC questionnaire for functional disability index for knee and hip (see text for details); DIFF: difficulty.

HHS Vulnerability Disclosure